Overview

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Panitumumab